获得的MYC重组可能与地幔细胞淋巴瘤中的ibrutinib耐药性有关

相关实验视频

Updated: Jan 9, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Chang-Tsu Yuan^1,2, Li-Yu Sun¹, Chieh-Lung Cheng³

¹Department and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

Virchows Archiv : an international journal of pathology

|December 3, 2025

概括

MYC重组和c-Myc过度表达与地细胞淋巴瘤 (MCL) 中的易布鲁替尼抗性有关. 识别MYC重组可能指导治疗策略,以改善MCL患者的治疗结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

甲细胞淋巴瘤 (MCL) 是一种B细胞淋巴瘤亚型.
易布鲁替尼改善了MCL治疗,但耐药性是一个问题.
在ibrutinib耐药性中MYC重组的作用尚不清楚.

研究的目的:

为了调查病理特征和MYC,BCL2,BCL6在抗易布鲁丁尼比抗易布鲁丁尼响应的MCL的重组.
确定MYC重组与MCL中的易布鲁替尼抗性之间的关联.

主要方法:

分析了来自27名患者的31个MCL瘤样本.
病理特征的比较,包括c-Myc表达和MYC,BCL2,BCL6重组状态,在耐药和响应性瘤之间.
在MYC重组瘤中评估细胞形态学,CD10表达和Ki-67指数.

主要成果:

在31个MCL瘤中,7个 (23%) 对ibrutinib有抗性.
抗易布鲁替尼的瘤显示出显著更高的c-Myc表达 (25%与5%) 和MYC重组 (43%与0%).
获得了MYC重组,并与布拉斯/多形形态形态,CD10表达和高增殖有关.

结论:

c-Myc过度表达和MYC重组与MCL中的易布鲁替尼抗性有关.
MYC重组可能表明内在耐药性对ibrutinib.
检测MYC重组可以优化MCL治疗策略并改善患者的治疗结果.

关键词:

在BCL2重排的过程中.在BCL6重排的过程中.在MYC的重组中,MYC的重组.这是一次双重打击.易布鲁丁尼布的耐药性耐药性地膜细胞淋巴瘤是什么

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...